Summary:
Plasma ƒÀ-phenylethylamine (PEA We compared the plasma concentration of PEA in PD patients and in control subjects. For 8 patients with PD (patients 2, 9, 14, 21, 22, 24, 25, and 26, as shown in Table 1 ), plasma PEA levels were measured consecutively at one and two years after the first measurement of plasma PEA. These patients were neurologically evaluated for the severity of Hoehn and Yahr stage. Changes in the plasma PEA level were also compared with the severity.
With the subjects' informed consent, 7ml of fasting venous blood was drawn into a plastic tube containing EDTA-K2 in the morning between 8:00 and 9:00 AM after bed rest for 30 min. They were not allowed to eat cheese or chocolate, or drink wine for a few days, and no drugs were taken in the A statistical comparison between the PD patients and control subjects was performed using Student's T-test (two tailed) for subjective data. The relation between severity of disease in PD patients and plasma PEA concentration was analyzed using Pearson's correlation. A p-value of less than 0.05 was regarded as a significant difference. 
RESULTS

DISCUSSION
The values of plasma PEA concentrations were similar to those of previous reports [14, 15] . PEA is a biogenic amine found in the nervous tissue of vertebrate and invertebrate species [2,16,17] . Its highest concentration has been reported to exist in mesolimbic and caudate-putamen structures [16, 17] . There has been much discussion about whether PEA has some physiological role. PEA has been related to depression [ 18, 19] , schizophrenia [20, 21 ] , and aggressive disorders [22] . PEA also acts on presynaptic dopaminergic nerve terminals and stimulates dopamine release [4, 23] . We previously reported that the CSF PEA level in PD was lower than in agedmatched controls [11] . Likewise, the present result showed a significantly decreased level of plasma PEA in PD patients because PEA easily crosses the blood-brain barrier [24] . Recently, Satoi et al. reported that the CSF PEA level was significantly lower in patients with Rett syndrome, and proposed that the CSF PEA level might reflect dopamine system impairment in Rett syndrome patients [25] . The present study suggested that the decreased level of plasma PEA in patients with PD is due to the degeneration of the nigral dopaminergic neurons diminishing the synthesis of PEA. Otherwise, it is also probable that changes in MAO-B activity are capable of altering the catabolism of PEA. However, prior studies have shown controversial results regarding changes in platelet MAO-B activity in patients with PD. The activity of this enzyme in patients with PD has been variously reported to be reduced [26] , to show no difference [27] [28] [29] We found that the plasma level of PEA was not coorrelated with the severity of Hohen and Yahr stage though the CSF level of PEA showed a negative correlation [11] . Plasma PEA levels are probably more influenced by many other factors, such as hydration, plasma protein concentration, tissue production, and metabolism of PEA than is CSF PEA. Although we found no correlation between the concentration of PEA in plasma and dose of levodopa, some factors affected the level of plasma PEA, in particular the issue of the effect of antiparkinsonian drugs. The normal concentration of dopamine in the putamen and caudate nucleus, the so-called dopaminergic nigrostriatal pathway, is reduced by at least 80% in PD patients [33] . As the present result showed a significantly decreased level of plasma PEA in patients with PD, which is enough to suggest that dopaminergic neuronal degeneration can cause a reduction in the plasma level of PEA. As yet a definite marker of the progression of PD has not been established.
In the present study, plasma PEA was measured serially for 3 years. Plasma level of PEA showed a downward trend in 5 patients in the progressive group, while on the other hand, the level remained unchanged in 3 patients in the non-progressive group. These results suggested that plasma concentrations of PEA correlated with the disease's clinical course in the individual patients, although no significant correlation was found with the severity of Hohen and Yahr stage. Measurement of plasma PEA might be a biological marker in the clinical course of PD, and provide an approach to rate the disease' s progression.
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